Molnupiravir To Reach 105 LMICs Through MPP Agreement
Almost 30 Generics Manufacturers Will Be Producing Low-Cost Versions Of The Antiviral
Executive Summary
Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.